GeneDx Holdings CEO sells over $121k in stock By Investing.com

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland recently engaged in transactions involving the company’s Class A Common Stock, according to the latest SEC filings. Stueland sold a total of 3,639 shares at a price of $33.33, totaling over $121,287. These transactions were executed on September 9, 2024, and were reported to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

The sale was part of a “sell to cover” transaction, a common practice where executives sell a portion of their stock to pay for the taxes due upon the vesting of their RSUs. The filings noted that these sales were specifically to satisfy tax withholding obligations.

In addition to the sales, the same SEC filings indicated that Stueland acquired 6,546 RSUs, which represent a contingent right to receive an equivalent number of shares of GeneDx Holdings Corp.’s Class A Common Stock at no cost. These units are part of a vesting plan that commenced on March 9, 2023, with a 6.25% vesting in quarterly installments over four years, provided that Stueland continues her service with the company.

Following these transactions, the CEO’s ownership in the company stands at 95,457 shares of Class A Common Stock. Investors often monitor the buying and selling activities of executives as these can provide insights into their confidence in the company’s future performance.

GeneDx Holdings Corp., previously known as Sema4 Holdings Corp. and before that CM Life Sciences, Inc., is a company incorporated in Delaware, operating in the health services sector. The company’s business address is in Stamford, Connecticut.

The reported transactions provide a glimpse into the movements of GeneDx Holdings Corp.’s stock by one of its top executives and offer investors a piece of the company’s insider trading activities.

In other recent news, genetic testing company GeneDx has been making significant strides in its financial performance. The firm recently posted a 16% sales beat and a 52% year-over-year growth, largely due to an increase in higher-priced exome and genome sequencing services. Furthermore, the company has seen a substantial decrease in its cash burn both yearly and quarterly.

TD Cowen, an analyst firm, has acknowledged these improvements and upgraded GeneDx’s price target to $50.00, maintaining a Buy rating on the shares. Similarly, BTIG raised their price target for GeneDx to $45, reflecting confidence in the company’s financial discipline and trajectory towards profitability.

In addition to these upgrades, GeneDx has raised its revenue guidance for the year and expects to be profitable by 2025. The company’s commitment to strong corporate governance was demonstrated in their Annual Meeting of Stockholders, where three Class III directors were elected and Ernst & Young LLP was ratified as the independent auditor. These recent developments indicate a positive trajectory for GeneDx in the evolving genetic testing market.

InvestingPro Insights

GeneDx Holdings Corp. (NASDAQ:WGS), with a market capitalization of $947.07 million, has been making waves in the market according to recent data from InvestingPro. The stock has experienced a significant return over the last week, with a 1-week price total return of 8.09%. This is indicative of the company’s recent performance and investor interest.

Despite a challenging profitability outlook, with analysts not anticipating the company to be profitable this year and a negative P/E ratio of -7.72, GeneDx Holdings Corp. has shown impressive growth in its share price. Over the last six months, the stock has seen a large price uptick with a 6-month price total return of 245.86%. Additionally, the company’s stock is trading near its 52-week high, at 94.15% of the peak value, signaling strong market confidence.

An InvestingPro Tip worth noting is that GeneDx Holdings Corp. operates with a moderate level of debt, which can be a stabilizing factor for potential investors. Furthermore, the company’s liquid assets exceed its short-term obligations, indicating a solid financial position in terms of liquidity.

For investors seeking more comprehensive analyses and metrics, InvestingPro offers additional tips on GeneDx Holdings Corp. at https://www.investing.com/pro/WGS. With many more InvestingPro Tips available, investors can gain deeper insights into the company’s financial health and market performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.